Drug Search Results

Losmapimod

Alternative Names: losmapimod, gw856553, gw856553x, gs856553
Latest Update: 2024-12-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MAPK Inhibitor,Immunomodulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation:
Fast Track - Muscular Dystrophies|Muscular Dystrophy, Facioscapulohumeral
Orphan Drug - Muscular Dystrophies|Muscular Dystrophy, Facioscapulohumeral *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Muscular Dystrophy, Facioscapulohumeral

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2022-000389-16	P3	Active, not recruiting	Muscular Dystrophy, Facioscapulohumeral	2024-09-30
2019-001181-15	P2	Active, not recruiting	Muscular Dystrophy, Facioscapulohumeral	2020-04-17

Recent News Events

Date	Type	Title
09/13/2024	News Article	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/12/2024	News Article	FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
09/12/2024	News Article	Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
08/27/2024	News Article	Fulcrum Therapeutics to Participate in Upcoming September Conferences
05/01/2024	PubMed	Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
04/01/2024	PubMed	Vitamin D3 inhibits p38 MAPK and senescence-associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing.
09/30/2023	PubMed	Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions